StockData
Exagen Inc. logo

Exagen Inc. (XGN) stock

XGNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3010% above fair value
$3.76−0.01 (-0.27%)

Close on Nov 17, 2026Market cap $91.09MP/E –Yield –

Exagen r&d expenses

Research and development expenses are spending on new products and technology.

Exagen's R&D Expenses for the twelve months ending Jun 30, 2026 was $6.47M, up 9.5% year over year. For fiscal 2025 it was $6.25M, up 16.4% from the year before. The highest annual figure on record is $9.88M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$6.25M+16.4%
FY2024Dec 31, 2024$5.38M+10.5%
FY2023Dec 31, 2023$4.87M-50.7%
FY2022Dec 31, 2022$9.88M+36.5%
FY2021Dec 31, 2021$7.24M+102.8%
FY2020Dec 31, 2020$3.57M+64.0%
FY2019Dec 31, 2019$2.18M+2.4%
FY2018Dec 31, 2018$2.13M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.43M-3.8%
Q1 FY2026Mar 31, 2026$1.55M+21.0%
Q4 FY2025Dec 31, 2025$1.76M+6.1%
Q3 FY2025Sep 30, 2025$1.73M+16.8%
Q2 FY2025Jun 30, 2025$1.48M+25.8%
Q1 FY2025Mar 31, 2025$1.28M+21.2%
Q4 FY2024Dec 31, 2024$1.66M+53.9%
Q3 FY2024Sep 30, 2024$1.48M+5.8%
Q2 FY2024Jun 30, 2024$1.18M-6.7%
Q1 FY2024Mar 31, 2024$1.06M-6.0%
Q4 FY2023Dec 31, 2023$1.08M-60.2%
Q3 FY2023Sep 30, 2023$1.40M-41.2%
Q2 FY2023Jun 30, 2023$1.26M-53.0%
Q1 FY2023Mar 31, 2023$1.13M-46.5%
Q4 FY2022Dec 31, 2022$2.70M+22.7%
Q3 FY2022Sep 30, 2022$2.38M+36.9%
Q2 FY2022Jun 30, 2022$2.69M+42.1%
Q1 FY2022Mar 31, 2022$2.10M+50.0%
Q4 FY2021Dec 31, 2021$2.20M+89.0%
Q3 FY2021Sep 30, 2021$1.74M+70.9%
Q2 FY2021Jun 30, 2021$1.89M+151.9%
Q1 FY2021Mar 31, 2021$1.40M+121.3%
Q4 FY2020Dec 31, 2020$1.17M+105.8%
Q3 FY2020Sep 30, 2020$1.02M+100.8%
Q2 FY2020Jun 30, 2020$751.00K+27.3%
Q1 FY2020Mar 31, 2020$634.00K+23.6%
Q4 FY2019Dec 31, 2019$566.00K+6.2%
Q3 FY2019Sep 30, 2019$507.00K-3.4%
Q2 FY2019Jun 30, 2019$590.00K–
Q1 FY2019Mar 31, 2019$513.00K–
Q4 FY2018Dec 31, 2018$533.00K–
Q3 FY2018Sep 30, 2018$525.00K–

More Exagen figures

See a number that looks wrong?